Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiota and host gastrointestinal environment refers to the highly diverse community of microorganisms—primarily bacteria but also archaea, fungi, and viruses—that inhabit the human digestive tract, as well as the host tissues and milieu in which they reside. This ecosystem interacts extensively with the host, impacting digestion, nutrition, immune function, metabolic regulation, and even behavior through the production of bioactive metabolites and modulation of host signaling pathways. Disruption of this microbial community (dysbiosis) is associated with numerous diseases, making the gut microbiota a major focus for therapeutic and diagnostic interventions, although it is not itself a discrete molecular target.
Direct modulation of microbial composition (antimicrobials, probiotics); Modulation of host immune signaling; Altering microbial metabolic output (e.g., SCFA production); Restoration of microbial diversity (FMT)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota and host gastrointestinal environment.